Massimo Giuseppe Colombo
#134,322
Most Influential Person Now
Massimo Giuseppe Colombo's AcademicInfluence.com Rankings
Massimo Giuseppe Colombomedical Degrees
Medical
#2300
World Rank
#2715
Historical Rank
Epidemiology
#402
World Rank
#421
Historical Rank
Download Badge
Medical
Why Is Massimo Giuseppe Colombo Influential?
(Suggest an Edit or Addition)Massimo Giuseppe Colombo's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Epidemiology of hepatocellular carcinoma. (1995) (1405)
- Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels (2002) (1371)
- Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. (2018) (1034)
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) (881)
- Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease (2007) (850)
- An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. (2009) (499)
- Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. (2016) (425)
- ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. (2014) (397)
- Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients (2003) (387)
- Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis (2010) (372)
- Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. (1983) (357)
- Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. (2007) (333)
- Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment (2017) (324)
- A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis (2012) (312)
- Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. (2012) (307)
- PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. (2016) (303)
- Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine (2005) (294)
- The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis (2009) (252)
- Patatin‐Like phospholipase domain‐containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C (2011) (244)
- Adefovir dipivoxil for wait‐listed and post–liver transplantation patients with lamivudine‐resistant hepatitis B: Final long‐term results (2007) (237)
- Transmission of Hepatitis A to Patients with Hemophilia by Factor VIII Concentrates Treated with Organic Solvent and Detergent To Inactivate Viruses (1994) (232)
- Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. (2017) (225)
- Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. (2017) (216)
- Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. (2010) (215)
- The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B (2017) (214)
- Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis (2017) (198)
- A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum (1997) (184)
- MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals (2017) (180)
- Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. (2012) (166)
- Micro-elimination - A path to global elimination of hepatitis C. (2017) (165)
- TRANSMISSION OF NON-A, NON-B HEPATITIS BY HEAT-TREATED FACTOR VIII CONCENTRATE (1985) (164)
- The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations (2018) (160)
- IL28B polymorphisms predict interferon‐related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen–negative patients with chronic hepatitis B (2013) (159)
- Production of Profibrotic Cytokines by Invariant NKT Cells Characterizes Cirrhosis Progression in Chronic Viral Hepatitis1 (2004) (155)
- The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. (2013) (148)
- Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. (2015) (147)
- The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. (1992) (143)
- Transient elastography predicts fibrosis progression in patients with recurrent hepatitis C after liver transplantation (2008) (143)
- High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. (1990) (140)
- Genetic variation in the interleukin‐28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection (2011) (136)
- Treatment With LedipasvirSofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection (2016) (134)
- Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. (2011) (130)
- Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B (2012) (118)
- A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. (2003) (117)
- High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity (2001) (113)
- Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. (2016) (111)
- A Prospective Multicenter Study of Hepatocellular Carcinoma in Italian Hemophiliacs With Chronic Hepatitis C (1998) (111)
- The natural history of hepatocellular carcinoma. (1992) (111)
- Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). (2014) (107)
- Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. (2016) (105)
- A multicenter randomized controlled trial of recombinant interferon‐α2b in patients with acute transfusion‐associated hepatitis C (1994) (103)
- Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management (2012) (102)
- A review of the treatment of chronic hepatitis C virus infection in cirrhosis. (2010) (101)
- Ultrasound-assisted percutaneous liver biopsy: superiority of the Tru-Cut over the Menghini needle for diagnosis of cirrhosis. (1988) (98)
- Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C (2012) (94)
- In situ characterization by monoclonal antibodies of the mononuclear cell infiltrate in chronic active hepatitis. (1983) (93)
- Y chromosome loss in male patients with primary biliary cirrhosis. (2013) (90)
- Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4 (2012) (89)
- Chronic Hepatitis in Carriers of Hepatitis B Surface Antigen, with Intrahepatic Expression of the Delta Antigen (1983) (87)
- Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. (1998) (85)
- A multicenter, prospective study of posttransfusion hepatitis in milan (1987) (83)
- VIRUCIDAL TREATMENT OF CLOTTING FACTOR CONCENTRATES (1988) (82)
- Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine‐resistant mutants (2005) (77)
- Direct-acting antivirals: the endgame for hepatitis C? (2017) (76)
- Dual cut‐off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation (2011) (76)
- Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. (2018) (75)
- Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients (2005) (73)
- Natural killer cell phenotype modulation and natural killer/T‐cell interplay in nucleos(t)ide analogue‐treated hepatitis e antigen‐negative patients with chronic hepatitis B (2015) (73)
- Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. (2012) (71)
- Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct‐Acting Antivirals for HCV Infection (2019) (69)
- Cytoplasmic Rods and Rings Autoantibodies Developed during Pegylated Interferon and Ribavirin Therapy in Patients with Chronic Hepatitis C (2012) (67)
- Serum type III procollagen peptide and laminin (Lam‐P1) detect alcoholic hepatitis in chronic alcohol abusers (1989) (64)
- NAFLD — sounding the alarm on a silent epidemic (2020) (63)
- High Serum Levels of HDV RNA Are Predictors of Cirrhosis and Liver Cancer in Patients with Chronic Hepatitis Delta (2014) (63)
- Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. (2013) (61)
- Patatin‐like phospholipase domain‐containing 3 I148M affects liver steatosis in patients with chronic hepatitis B (2013) (61)
- A Multicenter Controlled, Randomized, Open Trial of Interferon α2b Treatment of Anti–Human Immunodeficiency Virus-Negative Hemophilic Patients With Chronic Hepatitis C (1997) (59)
- Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients (2015) (57)
- Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. (2014) (56)
- The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? (2021) (56)
- Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group. (1990) (56)
- Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma (2011) (56)
- Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour (1988) (56)
- Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis (2017) (53)
- A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C (1996) (53)
- Nonprogressive course of non-A, non-B chronic hepatitis in multitransfused hemophiliacs. (1982) (52)
- Serum type III procollagen peptide in alcoholic liver disease and idiopathic hemochromatosis: Its relationship to hepatic fibrosis, activity of the disease and iron overload (1985) (52)
- Lack of association between type of hepatitis C virus, serum load and severity of liver disease (1996) (52)
- Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis (2016) (51)
- Total HCV core antigen assay: A new marker of hepatitis C viremia for monitoring the progress of therapy (2003) (48)
- Immune response to hepatitis B virus in children with papular acrodermatitis. (1977) (48)
- Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B (2010) (48)
- Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. (1989) (48)
- Suboptimal response to hepatitis B vaccine in drug users. (1991) (47)
- The Course of Esophageal Varices in Patients with Hepatitis C Cirrhosis Responding to Interferon/ Ribavirin Therapy (2011) (46)
- Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough (2002) (45)
- Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. (2006) (44)
- Revision of the Protocol Recommended for Studies of Safety from Hepatitis of Clotting Factor Concentrates (1989) (44)
- A clinicopathological study of liver disease in haemophiliacs. (1978) (44)
- Transient elastography in the assessment of liver fibrosis in adult thalassemia patients (2010) (44)
- Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection (2013) (43)
- A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. (1998) (42)
- Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection. (2016) (41)
- Diversity of antinuclear antibody responses in hepatocellular carcinoma. (1997) (40)
- TT virus is present in a high frequency of Italian hemophilic patients transfused with plasma-derived clotting factor concentrates. (1999) (40)
- Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. (2014) (40)
- Detection of hepatitis B virus DNA in formalin-fixed, paraffin-embedded liver tissue by the polymerase chain reaction. (1990) (40)
- Hepatitis B vaccination of 113 hemophiliacs: Lower antibody response in anti‐LAV/HTLV‐III‐positive patients (1986) (38)
- The pattern of pegylated interferon-α2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype (2009) (38)
- Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus‐related cirrhosis who attained sustained virological response (2017) (37)
- Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy (2013) (37)
- Metabolic syndrome after liver transplantation: short-term prevalence and pre- and post-operative risk factors. (2013) (37)
- Persistent elevation of the aminoterminal peptide of procollagen type III in serum of patients with acute viral hepatitis distinguishes chronic active hepatitis from resolving or chronic persistent hepatitis. (1986) (35)
- Drug safety evaluation of adefovir in HBV infection (2011) (35)
- High prevalence of TT virus (TTV) in naive chimpanzees and in hepatitis C virus-infected humans: frequent mixed infections and identification of new TTV genotypes in chimpanzees. (2000) (35)
- Antibody to hepatitis C virus after a vapour-heated factor VIII concentrate. The Study Group of the Fondazione dell'Emofilia. (1990) (34)
- Transient elastography identifies liver recipients with nonviral graft disease after transplantation: A guide for liver biopsy (2012) (34)
- Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. (2020) (34)
- A non-invasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internal-external validation. (2008) (34)
- The combination of PIVKA‐II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long‐term oral therapy (2020) (33)
- Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays. (1996) (32)
- DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection (2015) (32)
- Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. (2002) (32)
- Liver biopsy in hemophilia. (1978) (31)
- Serum Levels of Hepatitis C Virus Core Antigen as a Marker of Infection and Response to Therapy (2004) (31)
- Albumin and collagen gene regulation in alcohol- and virus-induced human liver disease. (1990) (30)
- Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. (2013) (30)
- Should surveillance for liver cancer be modified in hepatitis C patients after treatment‐related cirrhosis regression? (2016) (29)
- High rates of hepatitis G virus infection in multitransfused patients with hemophilia. (1997) (28)
- Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon (2016) (28)
- NON-A, NON-B HEPATITIS AFTER FACTOR VIII CONCENTRATE TREATED BY HEATING AND CHLOROFORM (1985) (27)
- Novel association of HLA-haplotypes with primary sclerosing cholangitis (PSC) in a southern European population. (2003) (27)
- Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. (2012) (27)
- Interferon–ribavirin therapy induces serum antibodies determining ‘rods and rings’ pattern in hepatitis C patients (2014) (27)
- An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs (2021) (26)
- Impaired Response to Interferon-α2B plus Ribavirin in Cirrhotic Patients with Genotype 3A Hepatitis C Virus Infection (2005) (25)
- Serum marker of type III procollagen in patients with idiopathic hemochromatosis and its relationship to hepatic fibrosis. (1983) (25)
- The significance of protein C antigen in acute and chronic liver biliary disease. (1985) (25)
- Elimination of hepatitis C in Europe: can WHO targets be achieved? (2020) (25)
- High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. (2006) (24)
- HBeAg‐negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues (2009) (24)
- Hepatotoxicity of immune check point inhibitors: Approach and management. (2019) (24)
- The Association of Il28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent (2013) (24)
- The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study. (2006) (24)
- The case for simplifying and using absolute targets for viral hepatitis elimination goals (2020) (24)
- Sofosbuvir‐based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature (2016) (24)
- High prevalence, low pathogenicity of hepatitis G virus in kidney transplant recipients. (2001) (23)
- Transmission of hepatitis G virus in patients with angioedema treated with steam‐heated plasma concentrates of C1 inhibitor (1998) (23)
- Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C (2009) (22)
- Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression (2018) (22)
- The risk of liver cancer in autoimmune liver diseases (2019) (22)
- Why do I treat HBeAg‐negative chronic hepatitis B patients with pegylated interferon? (2013) (21)
- Limited Utility of ITPA Deficiency to Predict Early Anemia in HCV Patients with Advanced Fibrosis Receiving Telaprevir (2014) (21)
- Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis (2017) (21)
- Long‐term titrated recombinant interferon‐α2a in chronic hepatitis C: a randomized controlled trial (1995) (21)
- Interferon in the treatment of chronic hepatitis C: a drug caught between past and future (2011) (20)
- Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis. (2012) (20)
- Treatment of Extrahepatic Manifestations of Hepatitis C Virus. (2017) (20)
- Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon (1995) (19)
- HCV genotype 3: an independent predictor of fibrosis progression in chronic hepatitis C. (2009) (19)
- T and B lymphocytes in patients with chronic active hepatitis (CAH). (1977) (19)
- Add‐on peginterferon alfa‐2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen‐negative chronic hepatitis B genotype D (2018) (19)
- Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation. (2009) (19)
- Endothelial protein C receptor plasma levels increase in chronic liver disease, while thrombomodulin plasma levels increase only in hepatocellular carcinoma. (2007) (19)
- ENDURANCE-4: Efficacy and Safety of ABT-493/ABT-530 Treatment in Patients with Chronic HCV Genotype 4, 5, or 6 Infection (2016) (19)
- Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes (2018) (19)
- Modulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C. (2011) (19)
- Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre (2015) (19)
- Safety of direct antiviral agents in real life. (2013) (18)
- Specificity of hepatitis C antibody ELISA in patients with haemophilia (1990) (18)
- No hepatitis after treatment with a modified factor IX concentrate in previously untreated hemophiliacs. (1985) (18)
- A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. (1997) (17)
- Immunogenicity of a recombinant hepatitis B vaccine in hemophiliacs (1988) (17)
- The impact of antiviral therapy on hepatocellular carcinoma epidemiology (2018) (17)
- Alpha interferon treatment of chronic hepatitis C. (1995) (17)
- Prevalence and genetic variants of hepatitis GB-C/HG and TT viruses in Gabon, equatorial Africa. (2000) (16)
- Sorafenib in advanced hepatocellular carcinoma: a further step toward personalized therapy of liver cancer. (2009) (16)
- The medical impact of hepatitis D virus infection in Uzbekistan (2019) (16)
- X chromosome contribution to the genetic architecture of primary biliary cholangitis. (2021) (16)
- Lymphocytes in liver diseases. (1986) (16)
- Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey (2017) (16)
- Long-Term Lamivudine Monotherapy in Renal-Transplant Recipients with Hepatitis-B-Related Cirrhosis (2005) (16)
- Excellence in Viral Hepatitis Elimination - Lessons from Georgia. (2019) (16)
- Telaprevir in a Patient with Chronic Hepatitis C and Cryoglobulinemic Glomerulonephritis (2014) (16)
- Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. (2011) (15)
- Virology of the Hepatitis A Epidemic in Italy (1994) (15)
- The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. (2009) (15)
- Studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype (2013) (15)
- Long-term evolution of anti-HCV-positive renal transplant recipients. (1998) (15)
- Treatment of chronic hepatitis C in Europe. (2003) (14)
- PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history (2013) (14)
- Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients (2014) (14)
- Treatment of patients with dual hepatitis B and C: a step in the right direction (2013) (14)
- Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients (1990) (14)
- The natural history of hepatitis C. (1996) (13)
- HIGH RISK OF RENAL IMPAIRMENT DURING LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IN PATIENTS WITH LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B (2009) (13)
- Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection (2016) (13)
- Viral hepatitis: "E" is for equitable elimination. (2018) (12)
- Transient elastography in the early prediction of progressive recurrent hepatitis C following liver transplantation (2010) (12)
- MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective (2021) (12)
- Treatment of HBeAg‐negative chronic hepatitis B with pegylated interferon (2011) (12)
- The natural history of hepatocellular carcinoma. (2002) (11)
- Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion. (1993) (11)
- Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity (2015) (11)
- No hepatitis recurrence using combination prophylaxis in HBV‐positive liver transplant recipients with YMDD mutants (2005) (11)
- HBV and HCV Therapy (2009) (11)
- Varying nuclear staining intensity of hepatitis B virus DNA in human hepatocellular carcinoma. (1986) (11)
- Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection (2012) (11)
- Management of HCV-Related Liver Disease in Hemophilia and Thalassemia (2018) (11)
- Minimal increases of serum alpha‐foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy (2019) (10)
- HCV therapy and risk of liver cancer recurrence: who to treat? (2018) (10)
- Ribavirin impairs salivary gland function in hepatitis c patients during combination treatment with pegylated interferon alfa-2a (2011) (10)
- Interferon‐α suppresses liver cell proliferation in patients with chronic hepatitis C virus infection (2005) (10)
- Lack of Rapid Virological Response Predicts Interferon-α2b/Ribavirin Therapy failure in HCV Genotype 2 Patients: A Single-Centre Study (2007) (10)
- Treatment of chronic hepatitis B: Update of the recommendations from the 2007 (2011) (9)
- Peginterferon Alfa-2B versus peginterferon Alfa-2A with ribavirin for the treatment of chronic hepatitis C: the pursuit of an ideal. (2010) (9)
- Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report (2018) (9)
- The Prevalence, Clinical Features and Response to Antiviral Therapy of Patients with Chronic Hepatitis C who are Seropositive for Liver–Kidney Microsome Type 1 Antibodies (2005) (9)
- IFNL4 rs368234815 and rs117648444 variants predict off‐treatment HBsAg seroclearance in IFN‐treated HBeAg‐negative chronic hepatitis B patients (2018) (9)
- Cirrhosis regression in chronic hepatitis C: an old tale with a new ending. (2009) (9)
- Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients (2011) (9)
- Twelve‐week posttreatment follow‐up predicts a sustained virological response to pegylated interferon and ribavirin therapy (2010) (9)
- The emerging picture of hepatitis C. (1991) (9)
- P.1.48: EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC HEPATITIS B (2011) (9)
- A global systematic review of hepatitis C elimination efforts through micro-elimination. (2022) (8)
- Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions (2019) (8)
- Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C (2014) (8)
- Daclatasvir for the treatment of chronic hepatitis C (2015) (8)
- Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients. (1990) (8)
- Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C (2015) (8)
- Implementation of HCV screening in the 1969–1989 birth‐cohort undergoing COVID‐19 vaccination (2022) (8)
- Genetic variation in interleukin-28B predicts hepatitis C treatment-induced viral clearance in genotype 1 patients: the dawn of a new era? (2010) (7)
- High prevalence but low pathogenicity of hepatitis G virus infection in Italian patients with genetic haemochromatosis. (1998) (7)
- Serum levels of hepatitis C virus RNA predict non‐response to interferon therapy: comparison of two commercial assays (1999) (7)
- Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response (2014) (7)
- Add-on PEG-IFN improves HBsAg kinetics in patients long-term fully suppressed by nucleos(t)ide analogs (2012) (7)
- EASL clinical practice guidelines for the management of occupational liver diseases (2020) (7)
- Feasibility and reproducibility of liver and pancreatic stiffness in patients with alcohol-related liver disease. (2019) (7)
- High prevalence of serum cryoglobulins in multitransfused hemophilic patients with chronic hepatitis C. (1998) (7)
- 731 EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B (2011) (7)
- Tenofovir monotherapy for naive patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months (2012) (7)
- Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports (2017) (7)
- T-9 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice (2012) (7)
- Long-Term Patient Centered Outcomes in Cirrhotic Patients with Chronic Hepatitis C After Achieving Sustained Virologic Response. (2021) (6)
- Interleukin 28B Genotype and Insulin Resistance in Chronic Hepatitis C Patients (2014) (6)
- Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? (2011) (6)
- Comparison of protocols for depleting anti-E. coli antibody in immunoblotting of recombinant antigens. (1996) (6)
- Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus. (2013) (6)
- Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis (2015) (6)
- Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B : a 4-year field practice, multicenter study (2012) (6)
- Deciding on Interferon-Free Treatment for Chronic Hepatitis C: Updating Liver Stiffness Cut-Off Values to Maximize Benefit (2016) (6)
- Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method. (1993) (6)
- T-12 Tenofovir suppressed viral suppression in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study (2013) (6)
- Acute hepatitis following assumption of a herbal remedy. (2008) (6)
- Can protocol liver biopsy be avoided to evaluate post-transplant hepatitis C recurrence? Transient elastography makes it possible. (2010) (6)
- Acute hepatitis B in children with papular acrodermatitis. (1986) (6)
- Postsustained Virological Response Management in Hepatitis C Patients (2020) (5)
- Response-Guided Duration of Direct Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future? (2017) (5)
- Glecaprevir/Pibrentasvir: The Final Piece in the Hepatitis C Virus Treatment Puzzle? (2018) (5)
- Towards precision medicine in NAFLD with PNPLA3 as a therapeutic target. (2019) (5)
- 99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin: 2016 (2015) (5)
- The eradication of HCV. (2016) (5)
- CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Randomized Study of Peginterferon-2a Plus Ribavirin vs Peginterferon-2b Plus Ribavirin in Chronic Hepatitis C (2010) (5)
- Patatin‐like phospholipase domain‐containing protein 3 genotype and hepatocellular carcinoma in chronic hepatitis C (2011) (5)
- Low accuracy of non-invasive tests for assessing residual cirrhosis in hepatitis C patients with a sustained virological response (2014) (5)
- Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management (2012) (5)
- Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma (2020) (5)
- Delta infection in the course of chronic hepatitis B. (1983) (5)
- Telaprevir for hepatitis C re-treatment: an open door on a long and winding road. (2010) (4)
- Low rates of naturally occurring resistant variants to the NS5A inhibitor daclatasvir in HCV‐1 null responders (2013) (4)
- 1318 FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C IS NOT INFLUENCED BY IL28B POLYMORPHISMS (2011) (4)
- Is there need for more than one IL28B single nucleotide polymorphism in hepatitis C clinical practice? (2013) (4)
- Many European countries 'flying blind' in their efforts to eliminate viral hepatitis (2017) (4)
- Treatment of chronic hepatitis C. (2003) (4)
- Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients (2013) (4)
- Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance. (2019) (4)
- Transient elastography (TE, Fibroscan) in the evaluation of recurrent disease after liver transplantation (LT) (2006) (4)
- Failure of adefovir 20 mg to improve suboptimal response in lamivudine‐resistant hepatitis B patients treated with adefovir 10 mg and lamivudine (2008) (4)
- The optimal ribavirin dose for patients infected with hepatitis C virus genotype 3: Should we utilize more? (2009) (4)
- Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. (2019) (4)
- Lamivudine prophylaxis prevents hepatitis b reactivation in HBsAg-negative/anti-HBc-positive patients undergoing Rituximab-based chemotherapy for non–hodgkin's B cell lymphoma (2015) (4)
- Specificity of the hepatitis C virus antibody ELISA in patients with hepatocellular carcinoma. (1990) (4)
- Treatment of hepatocellular carcinoma. (1994) (4)
- Serum procollagen type III peptide levels in patients with acute viral hepatitis (1988) (4)
- Hepatitis C eradication with DAA and risk of liver cancer recurrence: The debate unrests (2018) (4)
- Peginterferon maintenance therapy in patients with advanced hepatitis C to prevent hepatocellular carcinoma: the plot thickens. (2012) (4)
- A multicentre randomized clinical trial of recombinant alpha-2a interferon therapy in patients with chronic hepatitis B. (1993) (4)
- Predictors of psychopathological outcome during peg-interferon and ribavirin therapy in patients with chronic HCV-correlated hepatitis. (2013) (4)
- Original Articles: Viral HepatitisAdefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre– and post–liver transplantation patients☆ (2003) (4)
- Accelerating the elimination of hepatitis C in Kuwait: An expert opinion (2020) (4)
- Liver cell proliferation in patients with chronic hepatitis C is reduced by interferon therapy (2000) (3)
- Simvastatin Prevents Liver Microthrombosis and Sepsis Induced Coagulopathy in a Rat Model of Endotoxemia (2022) (3)
- Eliminating hepatitis C in Europe. (2019) (3)
- Liver disease and pathology in hemophilia. (2009) (3)
- HLA-DRB1 and tumor necrosis factor a but not cystic fibrosis transmembrane conductance regulator genes contribute to the genetic susceptibility of primary sclerosing cholangitis (2001) (3)
- Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma (2021) (3)
- Italian Migrants Study: an HCV and HBV Micro-Elimination Pilot Project (2021) (3)
- Long-term outcome of patients with HBeAg-negative chronic hepatitis B treated with a 24-month course of interferon alfa (2001) (3)
- Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. (2014) (3)
- Reproducibility of transient elastograpy (TE) in assessing hepatic fibrosis (2006) (3)
- Might rapid virological response be used as a stopping rule in liver transplant recipients treated with pegylated interferon plus ribavirin? (2008) (3)
- Long-term lamivudine therapy improves child-pugh score in patients with hepatitis B-related cirrhosis (2000) (3)
- Antiviral treatment of hepatitis C in renal transplant patients - safety issues (2017) (3)
- Hepatitis C genotype 3: a tough match for interferon-free regimens. (2014) (3)
- High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence (2021) (3)
- Hepatitis C virus and hepatocellular carcinoma. (1995) (3)
- Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study (2016) (3)
- Hepatitis B virus infection markers in chronic liver disease in Italy. The results of a multiregional investigation (1984) (3)
- Anti-LAV/HTLV-III antibodies in groups of individuals at high risk for infection in Italy (1985) (3)
- Predictive value of serum alpha-fetoprotein in cirrhosis. (1994) (3)
- Interferon-free oral therapy for hepatitis C: "faraway, so close!". (2012) (3)
- Natural History of Chronic Hepatitis B and Hepatocellular Carcinoma (2007) (2)
- Incidence of YMDD mutants, hepatocellular carcinoma and hepatic decompensation in patients with HBV-related cirrhosis treated long-term with lamivudine monotherapy (2001) (2)
- Genetic testing for hepatocellular carcinoma: an ambitious goal still to achieve. (2012) (2)
- No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered? (2016) (2)
- Is it time to recommend low-dose aspirin treatment for the prevention of hepatocellular carcinoma? (2020) (2)
- Recurrent liver disease after liver transplantation. (1997) (2)
- A 13-day, interferon-free regimen for chronic hepatitis C genotype 1 patients: between fear and hope. (2011) (2)
- Is Liver Injury an Affordable Risk of Immune Checkpoint Inhibitor Therapy for Cancer? (2018) (2)
- Spleen Stiffness Measurement By Transient Elastography As a Predictor of Bone Marrow Fibrosis in Primary Myelofibrosis Patients (2014) (2)
- Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study (2021) (2)
- 929e PEARL-II: Randomized Phase 3 Trial of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333 With or Without Ribavirin in Hepatitis C Virus Genotype 1b-Infected, Treatment-Experienced Patients (2014) (2)
- Blood T and B cells in patients with acute viral hepatitis A, B and non-A non-B. (1982) (2)
- Virus inactivation in clotting factor concentrates: Facts and fancies (1990) (2)
- HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection (2016) (2)
- Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma (2015) (2)
- Severe hepatic fibrosis in chronic hepatitis C (2006) (2)
- Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir (2012) (2)
- Pathway of care of hepatocellular carcinoma in 2017. (2016) (1)
- ANTI-PRE-S2 ANTIBODIES IN CLEARANCE OF HEPATITIS B VIRUS (1988) (1)
- Definition of healthy ranges for serum alanine aminotransferase concentration (2001) (1)
- Treatment of nonresponder patients with chronic hepatitis C: to repeat or not to repeat? That is the question. (2009) (1)
- Predictors of Alpha Interferon Response in Patients with Chronic Hepatitis C (1994) (1)
- Managing Patients With Nonalcoholic Fatty Liver Disease: Is It Really Only About Fibrosis? (2018) (1)
- Sustained Suppression of Hepatitis C by Pegylated Interferon and Ribavirin in Hemophilic Patients. (2004) (1)
- Practical insights into enhanced management of patients with HCV infection with direct antiviral agents. (2013) (1)
- Insulin resistance and response to telaprevir plus pegylated interferon and ribavirin: a requiem for the HOMA score? (2012) (1)
- Interferon Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B : reply (2003) (1)
- Viruses and Liver Cancer (2004) (1)
- NUCLEOS(T)IDE ANALOG THERAPY OF CHRONIC HEPATITIS B AND LIVER CANCER RISK REDUCTION: BETTER NUCLEOTIDES THAN NUCLEOSIDES? (2019) (1)
- Blood-borne viral infections in patients with von Willebrand disease: Prevalence and clinical correlation (2000) (1)
- ADULTHOOD GIANT-CELL HEPATITIS (1997) (1)
- Treatment of "problematic" hepatitis C patients. (1996) (1)
- Liver cell proliferation and severity of hepatitis C recurrence after liver transplant (2002) (1)
- Current Management of HBV Antiviral Drug Resistance (2011) (1)
- Randomized comparative study of recombinant alpha and lymphoblastoid interferon in patients with chronic active hepatitis C (1994) (1)
- Antibody to hepatitis C virus (anti-HCV) in hemophiliacs: A study with a second generation immunoenzymatic assay (ELISA) (1991) (1)
- Hepatitis C virus (HCV) antibodies in alcoholics (1990) (1)
- Management of lamivudine resistance: An overview (2008) (1)
- Contrast-enhanced ultrasound to diagnose small liver cancer in cirrhosis: friend or foe? (2010) (1)
- Is a 24 week treatment schedule with PegInterferon and Ribavirin too short for HCV genotype 3 cirrhotics? (2008) (1)
- HCVerso2: a phase III study of faldaprevir plus deleobuvir and ribavirin for chronic HCV genotype 1b infection in treatment naïve patients including those ineligible for pegylated interferon (2014) (1)
- Detecticn of hepatitis B virus (HBV) DNA in formalin-fixed. Paraffin-embedded liver tissue by polymerase chain reaction (1990) (1)
- Is there a real survival benefit of surveillance for hepatocellular carcinoma in cirrhotic patients? (2019) (1)
- Clinical experience with sterilized factor VIII concentrates (1987) (1)
- Images in hepatology. Adulthood giant-cell hepatitis. (1997) (1)
- Securing wider EU commitment to the elimination of hepatitis C virus (2022) (1)
- Cost Analysis of Residual Viremia Detected by Two Real-Time Pcr Assays For Response-Guided (Dual Or Triple) Therapy of Hcv Genotype 1 Infection. (2015) (1)
- Natural History of Hepatitis C Infection (2021) (1)
- Hepatitis C virus eradication with direct antiviral agents and liver cancer recurrence: Is the best the enemy of the good? (2017) (1)
- Serun procollagen in the development of chronic viral liver disease: Diagnostic value for chronic active hepatitis and response to immunosuppressive therapy (1982) (1)
- High prevalence of TT virus (TTV) infection in naive chimpanzees and in HCV positive humans. Identification of new TTV genotypes in chimpanzees (2000) (1)
- A rapid point-of-care test for the diagnosis of HCV infection: tipping the balance to screening extension beyond high risk populations? (2011) (1)
- Geographic differences in HBV related, autoimmune, and cryptogenic chronic active hepatitis. (2008) (1)
- Chemokine Receptor 5 Has No Major Role in the Severity of Hepatitis C Virus-Related Liver Damage. (2018) (1)
- The natural history of hepatitis C in renal allograft recipients: A 5-year prospective study in 443 patients (1995) (1)
- Climbing the Everest of lymph nodes staging in Cholangiocarcinoma. Close to the peak? (2021) (1)
- Nucleos(t)ide analogs-based chemoprevention of liver cancer in hepatitis B patients: effective, yet in search of optimization. (2013) (1)
- Tobe T, Kameda H, Okudaira M, Ohto M, Endo Y, Mito M, Okamoto E, Tanikawa K, Kojiro M, eds. Primary liver cancer in Japan. (2008) (1)
- Long-term outcome of hepatitis B in lamivudine-resistant cirrhotic patients (2002) (1)
- Rescue treatment with adefovir dipivoxil for lamivudine resistant patients pre- and post- liver transplantation (2003) (0)
- Analisi Economica Associata all'utilizzo Di Due Test (Real-Time PCR-Based) per Valutare La Determinazione Dell'HCV-RNA Nei Pazienti HCV Genotipo 1 in Trattamento Con Duplice o Triplice Terapia (2017) (0)
- Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era? (2015) (0)
- Clinical studies with treated clotting factor concentrates. (1987) (0)
- Title page (2016) (0)
- Intrafamilial transmission of hepatitis C virus (HCV): A study of sexual and household partners of 101 infected hemophiliacs (1991) (0)
- Patients With Chronic Hepatitis C Human Immunodeficiency Virus-Negative Hemophilic - Treatment of Anti 2b α A Multicenter Controlled, Randomized, Open Trial of Interferon (2013) (0)
- 559 hemophiliacs infected with the hepatitis C virus Six-month versus 12-month surveillance for hepatocellular carcinoma in (2013) (0)
- Long-term outcome of patients with HBaAg-negative chronic hepatitis B treated with a 24-month course of interferon alta (2001) (0)
- Predictors of Sustained Virological Response After Antiviral Therapy for Chronic Hepatitis C In Patients with Hemophilia: The Role of the Interleukin-28B (IL28B) Polymorphism (2011) (0)
- Reply: (2013) (0)
- Membro Editorial Board di Hepatology (2005) (0)
- Chronic Hepatitis C and HCC : What is new? (2018) (0)
- T-12 Rods and rings autoantibodies developing in chronic hepatitis C patients treated with peginterferon and ribavirin target inosine-5’-monophosphate dehydrogenase 2 (IMPDH2) (2012) (0)
- Who is who: The Editorial Board (3): E. Karol, M. Colombo (2005) (0)
- High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C. (2005) (0)
- Treatment with pegylated interferon (PegIFN) combined with ribavirin (Rbv) is the only option for preventing HCV-related end stage liver disease. (2012) (0)
- Editorial (2012) (0)
- Clinical and genetic markers of NAFLD and prediction of liver disease mortality. Ready for population screening? (2020) (0)
- SAT-493-Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma (2019) (0)
- ASIC — LIVER , PANCREAS , AND BILIARY RACT n Imbalance of Pro-vs AntiCoagulation Factors in Plasma From atients With Cirrhosis (0)
- Monitoring serum HBV-DNA during lamivudine therapy by quantitative PCR assay may predict development of YMDD mutants (2000) (0)
- Generation of Human Induced Pluripotent Stem Cells from Liver Progenitor Cells by Only Small Molecules (2010) (0)
- Peg-interferon and ribavirin therapy is safe and effective among HCV patients with thalassaemia major (2014) (0)
- Membro Editorial Board di Journal of Viral Hepatitis (2005) (0)
- Lamivudine treatment of chronic hepatitis B: evaluation of drug-resistance by the INNO-LiPA HBV DR (2001) (0)
- Cirrhosis regression in chronic hepatitis C: an old tale with a new ending. (2009) (0)
- Related articles (2012) (0)
- Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN (2017) (0)
- No recurrence using intramuscular anti-HBs immunoglobulins prophylaxis since the 1rst post-operative day combined with lamivudine after liver transplantation (2008) (0)
- High risk of aminotransferase flares in patients with chronic hepatitis C genotype 2 (2002) (0)
- liver disease in haemophiliacs . A clinicopathological study of (2005) (0)
- Rapid Communication Detection ofHepatitis BVirus DNAinFormalin- fixed, Paraffin-embedded Liver Tissue bythe Polymerase Chain Reaction (1990) (0)
- Asbestos exposure and increased risk of intrahepatic cholangiocarcinoma: enough to infer causality? (2020) (0)
- P464 RESISTANCE TO THROMBOMODULIN IS ASSOCIATED WITH DE NOVO PORTAL VEIN THROMBOSIS AND COULD BE A MODIFIABLE FACTOR TO IMPROVE PROGNOSIS IN PATIENTS WITH CIRRHOSIS (2014) (0)
- Clinical applications of in vitro tests for cell-mediated immunity in liver diseases. (1976) (0)
- Multicentre randomised controlled trial of recombinant interferon alfa-2b inpatients with acutenon-A, non-B/type Chepatitis after (1993) (0)
- Treatment of recurrent hepatitis C with interferon-free regimens: better starting early. (2015) (0)
- Optimizing Treatment with Pegylated Interferon-Ribavirin of Genotype 3 Chronic Hepatitis C: More Questions than Answers (2008) (0)
- Development of antibody to hepatitis C virus (HCV) in acute and chronic non-A, non-B post-transfusion hepatitis (1992) (0)
- Atezolizumab and bevacizumab in advanced HCC: ready for prime time? (2020) (0)
- A novel three-step immunoscintigraphy employing an anti-ferritin antibody to detect hepatocellular carcinoma (1995) (0)
- Usefulness of longitudinal assessment of AFP in DAA cured HCV cirrhotic patients to predict the developmente of HCC (2022) (0)
- The contribution of MHC region genes and the mutations of the CFTR gene in the genetic predisposition to primary sclerosing cholangitis (PSC) (2000) (0)
- Lights and Shadows on Fibrates as Second-Line Therapy of Primary Biliary Cholangitis. (2019) (0)
- Abstract No. 349: Treatment of HCC with Drug Eluting Beads Versus Microspheres before Transplant: Imaging and Hystology Results (2008) (0)
- The impact of severe fibrosis and antiviral therapy on the course of recurrent hepatitisC after liver tranplantation (2009) (0)
- Beta 2 microglobulin mutant W60C (2008) (0)
- Anemia during Pegylated Interferon-Ribavirin Therapy Results from Both Increase Suppression of Erythroid Differentiation and Hemolysis (2008) (0)
- [Altered immunoregulation in chronic viral hepatitis. Deficiency of T-lymphocytes with membrane receptors for histamine]. (1983) (0)
- infections in multitransfused hemophilic patients Serum hepatitis B virus DNA detects cryptic hepatitis B virus (2011) (0)
- Refining surgical therapy of liver cancer in cirrhosis: etiology makes the difference. (2018) (0)
- Serum autoantibodies are associated with severe recurrent hepatitis C after liver transplant (2009) (0)
- Pretransplant emergence of lamivudine mutants does not enhance the risk of HBV reactivation (2002) (0)
- COMPARISON OF ENHANCED LIVER FIBROSIS TEST AND TRANSIENT ELASTOGRAPHY FOR THE NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS B (2011) (0)
- Beta 2 microglobulin mutant D59P (2008) (0)
- [Pathogenesis of the chronic occurrence of hepatitis B]. (1983) (0)
- The Impact of the First Exposure to Different Blood Products on the Prevalence and Natural History of Hepatitis C Virus Infection in Von Willebrand Disease (VWD): Results from a Large Cohort Study Comparing VWD and Hemophilia Patients. (2004) (0)
- Interferon + ribavirin re-treatment in hemophilic patients relapsers or non-responders to interferon alone (2000) (0)
- Further insights into hepatitis C. (1991) (0)
- Cryptic hepatitis B virus replication during prednisone therapy in type B chronic active hepatitis (1987) (0)
- VIRUS EPATITICI E CARCINOMA EPATOCELLULARE (1993) (0)
- Viral kinetics in hbeag positive and negative patients with HBV-related cirrhosis treated long-term with lamivudine (2001) (0)
- injury in non-alcoholic steatohepatitis (NASH) liver: a tough problem to (2008) (0)
- Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (2021) (0)
- [Acute viral hepatitis: epidemiologic and clinical aspects]. (1980) (0)
- [Not Available]. (2013) (0)
- P143: Concordance between SVR4 and SVR24 in DAA Based Regimens: a real life experience including post‐liver transplant patients (2015) (0)
- Liver Fibrosis in Adult Thalassemia Patients Assessed by Transient Elastography. (2007) (0)
- Anemia during peginterferon-ribavirin therapy results from both increased suppression of erythroid differentiation and haemolysis (2008) (0)
- Sa1093 Inosine Triphosphastase (ITPA) Variants Predict Treatment-Induced Anemia, Ribavirin Dose-Reduction and Need for Erythropoietin Support During Peginterferon/Ribavirin Therapy for Chronic HCV (2012) (0)
- Serum pattern of aminotransferases in patients with chronic hepatitis C (2001) (0)
- [Not Available]. (1997) (0)
- [Prevalence and clinical significance of the intrahepatic delta agent in chronic HBsAg carriers]. (1982) (0)
- How to Optimize Treatment of Hepatitis C (2011) (0)
- Specificity of the anti-HCV elisa assay in hemophiliacs with persistently normal transaminases (1990) (0)
- Prevention of HCC by antiviral drugs (2006) (0)
- Reply to: “The “pegylated” story continues – Perhaps because both ends (α2a and α2b) are true?” (2012) (0)
- Epidemiology and characteristics of liver diseases in an immigrant population attending a nongovernmental organization (NGO) in Milan. (2017) (0)
- Accuracy of fine needle biopsy in lives lesions (1990) (0)
- Improving Transparency in Medical Journals (2007) (0)
- Reply (2003) (0)
- Pegylated interferons and ribavirin therapy for the treatment of chronic hepatitis C in thalassaemia major patients : preliminary results (2012) (0)
- In Vitro Effect of Ribavirin and Pegylated Interferon on Erythropoiesis (2008) (0)
- Transient Elastography (Fibroscan®) In Adult Patients with Inherited Bleeding Disorders and Chronic Hepatitis C. (2010) (0)
- [Early diagnosis and treatment of patients with liver carcinoma]. (1992) (0)
- Membro editorial board di The Lancet. Edizione italiana (2005) (0)
- Pre-transplant YMDD mutants without HBV recurrence in viremic liver graft recipients given continuos combined lavimudine/immunoprophylaxis (2003) (0)
- Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications (2020) (0)
- Hepatocellular carcinoma and hepatitis C virus: which should be treated first? (2020) (0)
- Prevention of biliary cancer with statins: still a long way to go. (2019) (0)
- Liver, Pancreas and Biliary Tract T of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre (2003) (0)
- 544 Accuracy of two new predictive models in assessing fibrosis in chronic hepatitis C (CHC) (2006) (0)
- Expanding transplantation of patients with a liver cancer without harming allocation: a priority in the era of scarce donation. (2017) (0)
- Proteomics to predict hepatitis C therapy outcome: where do we stand? (2012) (0)
- 388 DIFFERENT LEVELS OF HDV-RNA AND HBV-DNA AND DIFFERENT EXPRESSION OF HBSAG ARE ASSOCIATED TO DIFFERENT OUTCOMES IN CHRONIC HDV INFECTION (2011) (0)
- A letter of solidarity during the COVID‐19 pandemic (2020) (0)
- The international autoimmune hepatitis group scoring system in patients with chronic hepatitis C and serum autoantibodies undergoing interferon/ribavirin therapy : a prospective validation study (2006) (0)
- The role of serum alphafetoprotein determination in HCV-cirrhosis after antiviral treatment (2016) (0)
- Improving Transparency in Medical Journals. Authors' reply (2007) (0)
- Quantitation of HCV viremia in patients with chronic hepatitis assessed by second and third generation branched DNA (2002) (0)
- Optimal Management of Hepatitis C Genotype 2 Chronic Infection (2014) (0)
- Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy (2022) (0)
- Low Incidence of Hyperbilirubinemia Events With ABT-450/r-Ombitasvir and Dasabuvir With or Without Ribavirin in HCV Genotype-1 Infected Patients: 445 (2014) (0)
- Prevalence of serum antinuclear antibodies (ANA) after liver transplant in HCV and HBV recipients is associated with different clinical profiles (2006) (0)
- F-32 Cytoplasmic rings/rods autoantibodies; a novel serum antibody developing during peginterferon therapy in patients with chronic hepatits C (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Massimo Giuseppe Colombo?
Massimo Giuseppe Colombo is affiliated with the following schools:
